Globus Medical Inc. (GMED)
Here's Why Globus Medical (GMED) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Financial Strength Remains a Key Advantage for GMED
Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.
GMED's Robotics Leasing Shift Could Build Recurring Revenue
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.
GMED Growth Drivers After NuVasive and What Q1 Signals
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
Looking for a Growth Stock? 3 Reasons Why Globus Medical (GMED) is a Solid Choice
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) Upgraded to Strong Buy: Here's What You Should Know
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GMED vs. SONVY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Globus Medical (GMED)
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
Down 13.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Globus Medical (GMED)
The heavy selling pressure might have exhausted for Globus Medical (GMED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Globus Medical Q1 Earnings Call Highlights
Globus Medical NYSE: GMED reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and contributions from its Nevro acquisition.
